Vifor Pharma and Cara Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for Korsuva Injection in Hemodialysis Patients With Moderate-to-Severe Pruritus

St.Gallen, Switzerland, and Stamford, Conn., 8 March 2021–Vifor Pharma and Cara Therapeutics, Inc. (Nasdaq: CARA) today announced  that the U.S. Food and Drug Administration (FDA) has accepted and granted Priority Review for the New Drug...
Source: Drugs.com - New Drug Applications - Category: Drugs & Pharmacology Source Type: news